I think the key new Enhetu info is the unexpected efficacy with respect to brain met.
Nguyen
Enhertu additional analyses further reinforce ground-breaking efficacy in patients with HER2-positive metastatic breast cancer
https://www.astrazeneca.com/media-ce...st-cancer.html